OSI’s Oncology R & D approach incorporates state-of-the-art methods and technologies to help solve the challenges of cancer drug discovery and development. We are focused on the discovery of mechanism-based anti-cancer agents, particularly those that affect various drivers of Epithelial Mesenchymal Transition (EMT)-related processes in solid tumors. OSI scientists were among the first to suggest that the EMT status of a tumor may be an important determinant of sensitivity to molecular targeted therapies. These observations have profoundly impacted our approach to cancer drug discovery and clinical development, leading us to direct a significant portion of our research toward understanding the role of EMT in solid tumor progression, while at the same time focusing our efforts toward blockade of important EGFR-independent pathways.

OSI’s research team has developed considerable experience and know-how in medicinal and combinatorial chemistry and utilizes state-of-the-art high-throughput and structure-based means to identify and develop lead compound series. OSI’s Oncology research team has focused its expertise on building a range of target-driven screening assays for biochemical, cell-based, and animal model development. OSI believes in closely integrating its oncology research, clinical development, and regulatory affairs teams to drive our programs forward.

Research Overview

Capabilities